产品说明书
Ropivacaine HCl monohydrate
 |
同义名 : | 盐酸罗哌卡因 ;(–)-Ropivacaine (hydrochloride hydrate);LEA 103;(S)-Ropivacaine;Ropivacaine hydrochloride monohydrate |
| CAS号 : | 132112-35-7 | |
| 货号 : | A671024 | |
| 分子式 : | C17H29ClN2O2 | |
| 纯度 : | 99+% | |
| 分子量 : | 328.877 | |
| MDL号 : | MFCD00946578 | |
| 存储条件： |
粉末 Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(319.27 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 50 mg/mL(152.03 mM)，配合低频超声助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Ropivacaine hydrochloride monohydrate acts as a potent sodium channel blocker, inhibiting impulse conduction through reversible suppression of sodium ion influx in nerve fibers[1].[2]. Ropivacaine also functions as an inhibitor of the K2P (two-pore domain potassium channel) TREK-1, demonstrating an IC50 of 402.7 μM in the membranes of COS-7 cells[3]. Ropivacaine is commonly utilized in vivo for regional anesthesia and managing neuropathic pain[1]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02527577 | Liver Cancer, Adult | Not Applicable | Terminated(difficulties to rec... 展开 >>ruit patients) 收起 << | - | France ... 展开 >> CHU de SAINT-ETIENNE Saint-etienne, France, 42000 收起 << |
| NCT02438852 | Bladder Carcinoma ... 展开 >> Post-operative Pain 收起 << | Phase 3 | Not yet recruiting | February 25, 2022 | United States, California ... 展开 >> USC / Norris Comprehensive Cancer Center Not yet recruiting Los Angeles, California, United States, 90033 Contact: Ileana Aldana 323-865-3700 Ileana.aldana@med.usc.edu Principal Investigator: Siamak Daneshmand, MD Sub-Investigator: Brian Hu, MD 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.04mL 0.61mL 0.30mL |
15.20mL 3.04mL 1.52mL |
30.41mL 6.08mL 3.04mL |
| 参考文献 |
|---|